Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 224-314-4 | CAS number: 4303-67-7
Endpoint summary
Administrative data
Description of key information
An acute oral toxicity study was conducted on Laurylimidazole. The result of the study was:
The rat oral LD50 is 641 mg/kg when tested according to ANSI/ADA Doc No. 41A.
Key value for chemical safety assessment
Additional information
The acute oral toxicity potential of the test article (yellow liquid, purity 99% CASRN 4303-67-7, batch 0001) was tested in male and female CFY Sprague Dawley rats. The experimental procedure was based on ANSI/ADA Document number 41a 1982. The test article was administered as received via oral gavage. Rats (5/sex/group) received 400, 500, 640, or 1000 mg/kg test article. Clinical observations were recorded at 0.5, 1, 2, 3, 4, 5, and 6 hours after dosing (Day 1) and then at least once daily through Day 15. Body weights were recorded on Day 1, 4, 8, 15 and on the day of death. Surviving animals on Day 15 were euthanatized and received macroscopic necropsy examination. Animal(s) died in the 500 mg/kg (1/5 females), 640 mg/kg (2/5 males and 5/5 females), and 1000 mg/kg (4/5 males, 5/5 females) treated groups from Day 2 to Day 5. Animals that survived to Day 6 survived until the end of the study on Day 15. Animals that died prematurely had congestion of the stomach and pallor of the liver, kidneys, and/or spleen. Body weight losses were recorded for all rats found dead. Piloerection and increased salivation were observed in all rats. Hunched posture was observed in all animals except one male and one female of the 1000 mg/kg group. Clinical signs with dose dependent increases in incidence included: decreased respiratory rate, ptosis, pallor of the extremities, diarrhea, increased lachrymation, and prostration. Lethargy and abnormal gait (waddling) were observed in 3-5 animals/sex in the 400, 640, and 1000 mg/kg dose groups and only 1 female in the 500 mg/kg group. Body weight losses or decreased gains were recorded among surviving male rats of all groups on Day 4 and among surviving female rats on Days 4 and 8. All surviving rats achieved anticipated body weight gains during the second week of the study with the exclusion of one female rat that had slightly decreased gain on Day 15. Terminal necropsies were normal. The oral LD50 with a 95% confidence interval was calculated using probit analysis by a log transformation of the dose relative to percent mortality. Based on the results of this study (10% mortality at 500 mg/kg and increasing up to 90% mortality at 1000 mg/kg), the rat oral LD50 is 641 mg/kg with 95% confidence limits of 558 to 759 mg/kg.
Justification for classification or non-classification
The test article meets the CLP classification criteria for Acute Toxicity Category 4.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
